COVID-19 severity remains open to several questions. Researchers at the University of California Los Angeles (UCLA) have revealed how SARS-CoV-2 causes acute inflammation instead of the symptoms of a common cold. This effect could be initiated by the peptide fragments of the coronavirus released when the host eliminates the virus, which can form pro-inflammatory complexes that trigger an amplified immune response.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alterity, Avencell, Bayer, Bioxcel, Eli Lilly, Geovax, GSK, Irlab, Kancera, Kyowa Kirin, Lipocine, Mink, Sangamo, Sanofi, Thermosome, Ultragenyx, Vertex, Vividion.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4DMT, Amgen, CSL, Eyepoint, Iregene, Janssen, Ocuphire, Oragenics, Palatin, Pliant, Profoundbio, Rani, Triumvira.
Aligos Therapeutics Inc. and Katholieke Universiteit Leuven have jointly patented 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19), middle East respiratory syndrome coronavirus (MERS-CoV) infection, norovirus and rhinovirus infections.
COVID-19 severity remains open to several questions. Researchers at the University of California Los Angeles (UCLA) have revealed how SARS-CoV-2 causes acute inflammation instead of the symptoms of a common cold. This effect could be initiated by the peptide fragments of the coronavirus released when the host eliminates the virus, which can form pro-inflammatory complexes that trigger an amplified immune response.
Be it viral, nucleic acid or protein vaccines, recent efforts that led to the first regulatory approvals for not only COVID-19, but also for malaria and respiratory syncytial virus, positioned infectious diseases in the headlines for much of the last four years.
Be it viral, nucleic acid or protein vaccines, recent efforts that led to the first regulatory approvals for not only COVID-19, but also for malaria and respiratory syncytial virus, positioned infectious diseases in the headlines for much of the last four years. But despite that attention, or the threat of future pandemics, or the numerous infectious diseases for which there are no preventable vaccines and very little development activity, the level of private and public funding for biopharma companies working in the space is dismal – at least compared with that of oncology products, according to a new analysis report released by the Biotechnology Innovation Organization (BIO) on Jan. 25.
Capricor Therapeutics Inc.'s Stealthx exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of the U.S. Department of Health and Human Services' Project Nextgen initiative aimed at developing COVID-19 vaccines offering broader and more durable protection.
RSS
